Answers are grounded in this paper and cite their sources.
To assess cancer-specific mortality (CSM) and other-cause mortality (OCM) rates in patients with rare histological prostate cancer subtypes.
No takes yet. Share an insight, caveat, or question.
Siech et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: